EMEA and the evaluation of health-related quality of life data in the drug regulatory process.
about
Clearing up the hazy road from bench to bedside: a framework for integrating the fourth hurdle into translational medicineThe Role of Health-Related Quality of Life Data in the Drug Approval Processes in the US and EuropeA promising method for identifying cross-cultural differences in patient perspective: the use of Internet-based focus groups for content validation of new patient reported outcome assessments.Patient-reported outcomes in support of oncology product labeling claims: regulatory context and challenges.
P2860
EMEA and the evaluation of health-related quality of life data in the drug regulatory process.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
EMEA and the evaluation of hea ...... n the drug regulatory process.
@ast
EMEA and the evaluation of hea ...... n the drug regulatory process.
@en
type
label
EMEA and the evaluation of hea ...... n the drug regulatory process.
@ast
EMEA and the evaluation of hea ...... n the drug regulatory process.
@en
prefLabel
EMEA and the evaluation of hea ...... n the drug regulatory process.
@ast
EMEA and the evaluation of hea ...... n the drug regulatory process.
@en
P2093
P2860
P1476
EMEA and the evaluation of hea ...... n the drug regulatory process.
@en
P2093
David Sykes
Elias Mossialos
Sotiria Papanicolaou
P2860
P304
P356
10.1017/S0266462304001138
P577
2004-01-01T00:00:00Z